Copyright
©The Author(s) 2022.
World J Methodol. Jan 20, 2022; 12(1): 43-53
Published online Jan 20, 2022. doi: 10.5662/wjm.v12.i1.43
Published online Jan 20, 2022. doi: 10.5662/wjm.v12.i1.43
Table 2 Clinical trials related to antiangiogenic agent therapy and immunotherapy in colorectal cancer
| Status | Study title | Drugs | Country |
| Recruiting | A study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (Morpheus-CRC) | Regorafenib, atezolizumab | United States |
| Recruiting | Study of chemotherapy combination with autologous cell | Bevacizumab, oxaliplatin, capecitabine; Biological component: PD1-T cells | China |
| Recruiting | Treatment of colorectal liver metastases with immunotherapy and bevacizumab | Atezolizumab, bevacizumab, oxaliplatin | Korea |
| Recruiting | Neoadjuvant treatment in rectal cancer with radiotherapy followed by atezolizumab and bevacizumab (TARZAN) | Atezolizumab, bevacizumab | Netherlands |
| Not yet recruiting | Chemotherapy and immunotherapy as treatment for MSS metastatic | Capecitabine, oxaliplatin, bevacizumab, pembrolizumab | France |
| Not yet recruiting | QL1101 in combination with JS001 in patients with pMMR/MSS refractory metastatic | Bevacizumab, tripleitriumab | China |
| Not yet recruiting | Comparison of sintilimab to XELOX | Sintilimab vs XELOX + bevacizumab | China |
- Citation: Kampoli K, Foukas PG, Ntavatzikos A, Arkadopoulos N, Koumarianou A. Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer. World J Methodol 2022; 12(1): 43-53
- URL: https://www.wjgnet.com/2222-0682/full/v12/i1/43.htm
- DOI: https://dx.doi.org/10.5662/wjm.v12.i1.43